Regulation of ACSL4-Catalyzed Lipid Peroxidation Process Resists Cisplatin Ototoxicity

Feinan He1,2, Xiaotong Huang1,2, Guokun Wei1,2

  • 1Department of Otolaryngology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Insights

Cisplatin causes hearing loss via lipid peroxidation. Inhibiting ACSL4 reduces this damage, offering a potential preventive strategy for cisplatin ototoxicity.

Area of Science:

  • Ototoxicity research
  • Lipid peroxidation mechanisms
  • Cancer therapy side effects

Background:

  • Cisplatin is a vital chemotherapy agent but causes ototoxicity, leading to hearing loss.
  • Current methods to prevent cisplatin-induced ototoxicity are ineffective.
  • Lipid peroxidation is implicated in cellular damage, but its role in ototoxicity is not fully understood.

Purpose of the Study:

  • To investigate the role of ACSL4-catalyzed lipid peroxidation in cisplatin-induced hearing loss.
  • To explore potential protective mechanisms against cisplatin ototoxicity.
  • To evaluate ACSL4 inhibition as a preventive strategy.

Main Methods:

  • Utilized cisplatin ototoxicity models: HEI-OC1 cell line, cochlear explants, and zebrafish.
  • Measured cisplatin concentrations and assessed lipid peroxidation using CCK8 assay, immunofluorescence, MDA, 4-HNE, and C11-BODIPY probe.
  • Employed ferroptosis inhibitors (FER-1, Vit-E) and metabolomic assays.
  • Investigated ACSL4 expression and its inhibition in hair cells.

Main Results:

  • Cisplatin significantly increased lipid peroxidation, which was mitigated by ferroptosis inhibitors.
  • Metabolomic analysis revealed significant alterations in glutathione and arachidonic acid pathways.
  • ACSL4 was identified as a key enzyme regulating lipid peroxidation in cisplatin-treated hair cells.
  • Inhibiting ACSL4 reduced lipid peroxide levels and protected hair cells from cisplatin damage.

Conclusions:

  • ACSL4-catalyzed lipid peroxidation is a key contributor to cisplatin ototoxicity.
  • Inhibiting ACSL4 expression shows promise as an effective preventive measure against cisplatin-induced hearing loss.